About Solute carrier family 61 member 1
Solute carrier family 61 member 1 (SLC61A1) is a protein
from Homo sapiens identified by UniProt accession
Q6N075, 450 residues long.
MolForge cross-references it against 0 known binders and
9 disease associations.
Target properties
| Protein name | Solute carrier family 61 member 1 |
|---|
| UniProt accession | Q6N075 |
|---|
| Gene | SLC61A1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 450 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (9)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.38
- mean platelet volume · score 0.05
- bone density · score 0.02
- mean corpuscular volume · score 0.02
- erythrocyte count · score 0.02
- neoplasm · score 0.00
- retinal degeneration · score 0.00
- diabetes mellitus · score 0.00
- astrocytoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q6N075-F1 | alphafold | PREDICTED | 88.96 | — |
Amino-acid sequence (450 residues)
MLVTAYLAFV GLLASCLGLE LSRCRAKPPG RACSNPSFLR FQLDFYQVYF LALAADWLQA PYLYKLYQHY YFLEGQIAIL YVCGLASTVL FGLVASSLVD WLGRKNSCVL FSLTYSLCCL TKLSQDYFVL LVGRALGGLS TALLFSAFEA WYIHEHVERH DFPAEWIPAT FARAAFWNHV LAVVAGVAAE AVASWIGLGP VAPFVAAIPL LALAGALALR NWGENYDRQR AFSRTCAGGL RCLLSDRRVL LLGTIQALFE SVIFIFVFLW TPVLDPHGAP LGIIFSSFMA ASLLGSSLYR IATSKRYHLQ PMHLLSLAVL IVVFSLFMLT FSTSPGQESP VESFIAFLLI ELACGLYFPS MSFLRRKVIP ETEQAGVLNW FRVPLHSLAC LGLLVLHDSD RKTGTRNMFS ICSAVMVMAL LAVVGLFTVV RHDAELRVPS PTEEPYAPEL
Explore Solute carrier family 61 member 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets